icon-folder.gif   Conference Reports for NATAP  
  HEPDART 2015: Frontiers in
Drug Development for Viral Hepatitis
December 6-10 2015
Wailea, HI
Back grey_arrow_rt.gif
High Efficacy of Sofosbuvir/Velpatasvir In HCV Genotypes 1-6 Infected Patients With Cirrhosis: Pooled Data From the ASTRAL 1, 2 and 3 Trials
  Reported by jules Levin
HEPDART 2015, December 6-10, 2015, Wailea, Hawaii
T Asselah1*, M Sulkowski2, IM Jacobson3, T Morgan4, B Conway5, S Gordon6, ES Svarovskaia7, L Liu7, J McNally7, A Osinusi7, DM Brainard7, JG McHutchison7, JJ Feld8, GR Foster9
1University Paris Diderot, INSERM U773, Paris, France; 2Johns Hopkins University, Baltimore, US; 3Mount Sinai Beth Israel Medical Center, New York, US; 4VA Long Beach Healthcare System , Long Beach, US; 5Vancouver Infectious Diseases Centre, Vancouver, BC, Canada; 6Henry Ford Health System, Detroit, US; 7Gilead Sciences Inc., Foster City, US; 8Toronto Western Hospital Liver Centre, Toronto, Canada ; 9Queen Mary University of London, London
AASLD: Sofosbuvir+GS-5816 GT 1-6: ASTRAL-1, ASTRAL-2, ASTRAL-3, ASTRAL-4 - (12/09/15)
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection - (12/11/15)